BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 15837966)

  • 1. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma.
    Schöder H; Noy A; Gönen M; Weng L; Green D; Erdi YE; Larson SM; Yeung HW
    J Clin Oncol; 2005 Jul; 23(21):4643-51. PubMed ID: 15837966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of
    Alobthani G; Romanov V; Isohashi K; Matsunaga K; Watabe T; Kato H; Tatsumi M; Shimosegawa E; Hatazawa J
    Hell J Nucl Med; 2018; 21(1):7-14. PubMed ID: 29550841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does partial volume corrected maximum SUV based on count recovery coefficient in 3D-PET/CT correlate with clinical aggressiveness of non-Hodgkin's lymphoma?
    Tsujikawa T; Otsuka H; Morita N; Saegusa H; Kobayashi M; Okazawa H; Nishitani H
    Ann Nucl Med; 2008 Jan; 22(1):23-30. PubMed ID: 18250984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utilization of 18F-FDG PET/CT as a staging tool in patients with newly diagnosed lymphoma.
    Cho SF; Chang CC; Liu YC; Chang CS; Hsiao HH; Liu TC; Huang CT; Lin SF
    Kaohsiung J Med Sci; 2015 Mar; 31(3):130-7. PubMed ID: 25744235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Standardised uptake value of 18F-FDG on staging PET/CT in newly diagnosed patients with different subtypes of non-Hodgkin's lymphoma.
    Papajík T; Mysliveček M; Sedová Z; Buriánková E; Procházka V; Koranda P; Raida L; Kubová Z; Palová M; Kučerová L; Flodr P; Jarkovský J; Dušek L; Indrák K
    Eur J Haematol; 2011 Jan; 86(1):32-7. PubMed ID: 20874822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standardized uptake value based evaluation of lymphoma by FDG and FLT PET/CT.
    Wang R; Zhu H; Chen Y; Li C; Li F; Shen Z; Tian J; Yu L; Xu B
    Hematol Oncol; 2014 Sep; 32(3):126-32. PubMed ID: 23996464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma.
    Ngeow JYY; Quek RHH; Ng DCE; Hee SW; Tao M; Lim LC; Tan YH; Lim ST
    Ann Oncol; 2009 Sep; 20(9):1543-1547. PubMed ID: 19474116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual-time-point F-18 FDG PET/CT for evaluation in patients with malignant lymphoma.
    Shinya T; Fujii S; Asakura S; Taniguchi T; Yoshio K; Alafate A; Sato S; Yoshino T; Kanazawa S
    Ann Nucl Med; 2012 Oct; 26(8):616-21. PubMed ID: 22692457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Positron emission tomography with 18F-FDG compared with proliferative activity of tumor cells in different subtypes of non-Hodgkin lymphoma].
    Tiutin LA; Khodzsibekova MM; Pozharisskiĭ KM; Mukhina MS; Kostenikov NA; Il'in NV
    Vopr Onkol; 2011; 57(6):748-52. PubMed ID: 22416392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigating the existence of quantum metabolic values in non-Hodgkin's lymphoma by 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography.
    Wong CY; Thie J; Parling-Lynch KJ; Zakalik D; Wong RH; Gaskill M; Margolis JH; Hill J; Sukari A; Chundru S; Fink-Bennett D; Nagle C
    Mol Imaging Biol; 2007; 9(1):43-9. PubMed ID: 17176979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-body diffusion-weighted MRI and (18)F-FDG PET/CT can discriminate between different lymphoma subtypes.
    Mosavi F; Wassberg C; Selling J; Molin D; Ahlström H
    Clin Radiol; 2015 Nov; 70(11):1229-36. PubMed ID: 26208992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma.
    Bodet-Milin C; Kraeber-Bodéré F; Moreau P; Campion L; Dupas B; Le Gouill S
    Haematologica; 2008 Mar; 93(3):471-2. PubMed ID: 18310543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma.
    Blum RH; Seymour JF; Wirth A; MacManus M; Hicks RJ
    Clin Lymphoma; 2003 Jun; 4(1):43-9. PubMed ID: 12837154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma.
    Torizuka T; Nakamura F; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Kobayashi M; Ouchi Y
    Eur J Nucl Med Mol Imaging; 2004 Jan; 31(1):22-8. PubMed ID: 14574514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [18F]3'-deoxy-3'-fluorothymidine-PET in NHL patients: whole-body biodistribution and imaging of lymphoma manifestations--a pilot study.
    Buchmann I; Neumaier B; Schreckenberger M; Reske S
    Cancer Biother Radiopharm; 2004 Aug; 19(4):436-42. PubMed ID: 15453958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
    Pelosi E; Penna D; Deandreis D; Chiappella A; Skanjeti A; Vitolo U; Bisi G
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preliminary clinical assessment of dynamic 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for evaluating the clinicopathological grade in patients with non-Hodgkin's lymphoma: a prospective study.
    Shinya T; Otomi Y; Dimitrakopoulou-Strauss A; Kubo M; Kondo M; Otomo M; Terazawa K; Bando Y; Harada M
    Nucl Med Commun; 2020 Jan; 41(1):26-33. PubMed ID: 31800508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diffusely increased bone marrow FDG uptake in recently untreated lymphoma: incidence and relevance.
    Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
    Eur J Haematol; 2015 Jul; 95(1):83-9. PubMed ID: 25537478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of decreased uptake of 18F-fluorodeoxyglucose in the cerebral cortex of patients with intracranial non-Hodgkin's lymphoma lesions through PET/CT.
    Zhang Q; Tian T; Wang L; Qiu H; Li D
    Biomed Pharmacother; 2016 Dec; 84():1331-1336. PubMed ID: 27810790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphoma.
    Cremerius U; Fabry U; Neuerburg J; Zimny M; Bares R; Osieka R; Büll U
    Nuklearmedizin; 2001 Feb; 40(1):23-30. PubMed ID: 11373935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.